TY - JOUR
T1 - Recombinant PreS-fusion protein vaccine for birch pollen and apple allergy
AU - Khaitov, Musa
AU - Shilovskiy, Igor
AU - Valenta, Rudolf
AU - Weber, Milena
AU - Korneev, Artem
AU - Tulaeva, Inna
AU - Gattinger, Pia
AU - van Hage, Marianne
AU - Hofer, Gerhard
AU - Konradsen, Jon R
AU - Keller, Walter
AU - Akinfenwa, Oluwatoyin
AU - Poroshina, Alina
AU - Ilina, Nataliya
AU - Fedenko, Elena
AU - Elisyutina, Olga
AU - Litovkina, Alla
AU - Smolnikov, Evgenii
AU - Nikonova, Aleksandra
AU - Rybalkin, Sergei
AU - Aldobaev, Vladimir
AU - Smirnov, Valeriy
AU - Shershakova, Nadezhda
AU - Petukhova, Olga
AU - Kudlay, Dmitriy
AU - Shatilov, Artem
AU - Timofeeva, Anastasiya
AU - Campana, Raffaela
AU - Udin, Sergei
AU - Skvortsova, Veronica
N1 - Publisher Copyright:
© 2023 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
PY - 2023/10/19
Y1 - 2023/10/19
N2 - BACKGROUND: IgE cross-sensitization to major birch pollen allergen Bet v 1 and pathogenesis-related (PR10) plant food allergens is responsible for the pollen-food allergy syndrome.METHODS: We designed a recombinant protein, AB-PreS, consisting of non-allergenic peptides derived from the IgE-binding sites of Bet v 1 and the cross-reactive apple allergen, Mal d 1, fused to the PreS domain of HBV surface protein as immunological carrier. AB-PreS was expressed in E. coli and purified by chromatography. The allergenic and inflammatory activity of AB-PreS was tested using basophils and PBMCs from birch pollen allergic patients. The ability of antibodies induced by immunization of rabbits with AB-PreS and birch pollen extract-based vaccines to inhibit allergic patients IgE binding to Bet v 1 and Mal d 1 was assessed by ELISA.RESULTS: IgE-binding experiments and basophil activation test revealed the hypoallergenic nature of AB-PreS. AB-PreS induced lower T-cell activation and inflammatory cytokine production in cultured PBMCs from allergic patients. IgG antibodies induced by five injections with AB-PreS inhibited allergic patients' IgE binding to Bet v 1 and Mal d 1 better than did IgG induced by up to 30 injections of six licensed birch pollen allergen extract-based vaccines. Additionally, immunization with AB-PreS induced HBV-specific antibodies potentially protecting from infection with HBV.CONCLUSION: The recombinant AB-PreS-based vaccine is hypoallergenic and superior over currently registered allergen extract-based vaccines regarding the induction of blocking antibodies to Bet v 1 and Mal d 1 in animals.
AB - BACKGROUND: IgE cross-sensitization to major birch pollen allergen Bet v 1 and pathogenesis-related (PR10) plant food allergens is responsible for the pollen-food allergy syndrome.METHODS: We designed a recombinant protein, AB-PreS, consisting of non-allergenic peptides derived from the IgE-binding sites of Bet v 1 and the cross-reactive apple allergen, Mal d 1, fused to the PreS domain of HBV surface protein as immunological carrier. AB-PreS was expressed in E. coli and purified by chromatography. The allergenic and inflammatory activity of AB-PreS was tested using basophils and PBMCs from birch pollen allergic patients. The ability of antibodies induced by immunization of rabbits with AB-PreS and birch pollen extract-based vaccines to inhibit allergic patients IgE binding to Bet v 1 and Mal d 1 was assessed by ELISA.RESULTS: IgE-binding experiments and basophil activation test revealed the hypoallergenic nature of AB-PreS. AB-PreS induced lower T-cell activation and inflammatory cytokine production in cultured PBMCs from allergic patients. IgG antibodies induced by five injections with AB-PreS inhibited allergic patients' IgE binding to Bet v 1 and Mal d 1 better than did IgG induced by up to 30 injections of six licensed birch pollen allergen extract-based vaccines. Additionally, immunization with AB-PreS induced HBV-specific antibodies potentially protecting from infection with HBV.CONCLUSION: The recombinant AB-PreS-based vaccine is hypoallergenic and superior over currently registered allergen extract-based vaccines regarding the induction of blocking antibodies to Bet v 1 and Mal d 1 in animals.
UR - http://www.scopus.com/inward/record.url?scp=85174386968&partnerID=8YFLogxK
U2 - 10.1111/all.15919
DO - 10.1111/all.15919
M3 - Journal article
C2 - 37855043
SN - 0105-4538
JO - Allergy: European Journal of Allergy and Clinical Immunology
JF - Allergy: European Journal of Allergy and Clinical Immunology
ER -